Circulating Tumour DNA in Melanoma-Clinic Ready?
Biomarkers
Immunotherapy
Liquid biopsies
Melanoma
Targeted therapy
ctDNA
Journal
Current oncology reports
ISSN: 1534-6269
Titre abrégé: Curr Oncol Rep
Pays: United States
ID NLM: 100888967
Informations de publication
Date de publication:
03 2022
03 2022
Historique:
accepted:
04
10
2021
pubmed:
9
2
2022
medline:
26
4
2022
entrez:
8
2
2022
Statut:
ppublish
Résumé
Liquid biopsies, including circulating tumour DNA (ctDNA), can inform a variety of clinical questions. This review examines the potential role of ctDNA as a clinical tool to inform clinical decision-making from early to late stage cutaneous melanoma. In pre-clinical studies, ctDNA has been shown to detect minimal residual disease and molecular relapse; predict and monitor response to therapy; and identify key resistance mechanisms. Here, we examine the potential utility of ctDNA and discuss its limitations for use in patients with melanoma. We present novel clinical trials, which are testing its value as a tool to augment clinical decision-making. Finally, we discuss the steps that are needed to ensure that ctDNA is used optimally in order to improve outcomes for patients with melanoma. Preclinical studies have shown that ctDNA has huge potential to provide real-time information about disease status in patients with melanoma. It is now time to test it rigorously within clinical trials to assess how it can be optimally used to benefit patients in the clinic.
Identifiants
pubmed: 35133615
doi: 10.1007/s11912-021-01151-6
pii: 10.1007/s11912-021-01151-6
pmc: PMC8885536
doi:
Substances chimiques
Biomarkers, Tumor
0
Circulating Tumor DNA
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
363-373Subventions
Organisme : Cancer Research UK
ID : 27405
Pays : United Kingdom
Informations de copyright
© 2022. The Author(s).
Références
JCO Precis Oncol. 2020 Nov;4:20-31
pubmed: 35050727
Nat Commun. 2015 Nov 10;6:8839
pubmed: 26554728
Ann Oncol. 2018 Feb 1;29(2):490-496
pubmed: 29112704
Eur J Cancer. 2018 Jan;88:1-9
pubmed: 29175734
Nat Rev Clin Oncol. 2017 Aug;14(8):463-482
pubmed: 28374786
J Transl Med. 2019 Sep 5;17(1):303
pubmed: 31488153
Eur J Cancer. 2020 Jun;132:207-210
pubmed: 32388064
Ann Oncol. 2019 May 1;30(5):804-814
pubmed: 30838379
Ann Oncol. 2019 Mar 1;30(3):464-470
pubmed: 30475948
Br J Surg. 2021 Sep 27;108(9):1056-1063
pubmed: 33761533
Sci Transl Med. 2020 Jun 17;12(548):
pubmed: 32554709
EBioMedicine. 2019 Oct;48:178-190
pubmed: 31594749
Nat Rev Cancer. 2011 Jun;11(6):426-37
pubmed: 21562580
Clin Cancer Res. 2016 Feb 1;22(3):567-74
pubmed: 26446943
Sci Transl Med. 2015 Mar 18;7(279):279ra41
pubmed: 25787767
Clin Cancer Res. 2020 Nov 15;26(22):5926-5933
pubmed: 33067256
Cancer. 2020 Jan 1;126(1):86-97
pubmed: 31584722
Sci Transl Med. 2019 Aug 7;11(504):
pubmed: 31391323
J Neuropathol Exp Neurol. 2018 Jul 1;77(7):628-635
pubmed: 29873738
Sci Transl Med. 2018 Nov 7;10(466):
pubmed: 30404863
Clin Cancer Res. 2020 Aug 1;26(15):4064-4071
pubmed: 32321716
Sci Rep. 2015 Jun 22;5:11198
pubmed: 26095797
Ann Oncol. 2017 May 1;28(5):1130-1136
pubmed: 28327969
JCO Precis Oncol. 2017 Nov;1:1-14
pubmed: 35172485
J Invest Dermatol. 2015 Apr;135(4):1190-1193
pubmed: 25330295
Clin Cancer Res. 2012 Oct 1;18(19):5329-40
pubmed: 22850568
N Engl J Med. 2016 Nov 10;375(19):1845-1855
pubmed: 27717298
Am J Cancer Res. 2019 Aug 01;9(8):1546-1553
pubmed: 31497342
Mol Oncol. 2016 Jan;10(1):157-65
pubmed: 26440707
Oncotarget. 2016 Dec 20;7(51):85430-85436
pubmed: 27863426
J Clin Oncol. 2013 Sep 10;31(26):3205-11
pubmed: 23918947
Cancer Res. 2010 Jul 1;70(13):5213-9
pubmed: 20551059
J Transl Med. 2016 Apr 19;14:95
pubmed: 27095081
Cancer Epidemiol Biomarkers Prev. 1994 Jan-Feb;3(1):67-71
pubmed: 8118388
Nat Commun. 2017 Nov 28;8(1):1816
pubmed: 29180633
Br J Cancer. 2015 Jul 28;113(3):476-83
pubmed: 26125447
J Clin Endocrinol Metab. 1993 Apr;76(4):950-5
pubmed: 7682563
Trends Mol Med. 2021 May;27(5):482-500
pubmed: 33500194
Ann Oncol. 2019 May 1;30(5):815-822
pubmed: 30860590
JAMA Oncol. 2018 May 1;4(5):717-721
pubmed: 29423503
Nature. 2021 Jun;594(7863):418-423
pubmed: 33953400
Cancer Discov. 2016 Mar;6(3):286-99
pubmed: 26715644
Lancet. 2010 Oct 2;376(9747):1155-63
pubmed: 20888993
J Clin Oncol. 2018 Dec 10;36(35):3441-3449
pubmed: 30343620
J Clin Oncol. 2014 Nov 1;32(31):3483-9
pubmed: 24888818
CA Cancer J Clin. 2017 Nov;67(6):472-492
pubmed: 29028110
Nat Genet. 2016 Oct;48(10):1273-8
pubmed: 27571261
Lancet Oncol. 2018 May;19(5):603-615
pubmed: 29573941
Nat Rev Clin Oncol. 2019 Jul;16(7):409-424
pubmed: 30796368
Ann Oncol. 2016 Oct;27(10):1959-65
pubmed: 27502704
Oncotarget. 2018 May 18;9(38):25265-25276
pubmed: 29861869
Clin Cancer Res. 2019 Jul 15;25(14):4413-4421
pubmed: 30992299
N Engl J Med. 2020 Sep 17;383(12):1139-1148
pubmed: 32877599
Mol Clin Oncol. 2018 Jul;9(1):58-61
pubmed: 29977540
Cancers (Basel). 2020 Dec 16;12(12):
pubmed: 33339135
J Immunother Cancer. 2014 Dec 16;2(1):42
pubmed: 25516806
Nat Med. 2020 Oct;26(10):1564-1568
pubmed: 33020646
Oncotarget. 2015 Dec 8;6(39):42008-18
pubmed: 26524482
Immunology. 2005 May;115(1):55-62
pubmed: 15819697
BMC Cancer. 2018 Jul 9;18(1):726
pubmed: 29986670
Lancet Oncol. 2021 Mar;22(3):370-380
pubmed: 33587894
N Engl J Med. 2014 Nov 13;371(20):1877-88
pubmed: 25265492
Clin Chem. 2018 May;64(5):830-842
pubmed: 29483107
J Neurooncol. 2016 May;128(1):93-100
pubmed: 26961773
Sci Rep. 2020 Oct 29;10(1):18682
pubmed: 33122747
N Engl J Med. 2014 Nov 13;371(20):1867-76
pubmed: 25265494
Br J Cancer. 2021 Jan;124(2):345-358
pubmed: 32968207
Nat Med. 2019 Dec;25(12):1928-1937
pubmed: 31768066